Time Of Maximum Resolution Of Diabetic Macular Oedema After Ranibizumab Injection
Mohammed Abd El Wahab Hassan, Hossam ElDin Mohammed Khalil, Abd El Rahman Shaban Ahmed
Ophthalmology Department, Faculty of Medicine, Beni-Suef University, Egypt
Docto372@gmail.com , 01020612137

Abstract:
Introduction Macular edema occurs in a wide variety of ocular diseases, and an alteration in the blood–retinal barrier (BRB) leads to the accumulation of fluid in the extracellular space and the development of fluid-filled (cystoid) spaces in the outer plexiform layer and the inner nuclear layer of the retina are common findings in cystoid macular edema (CME).
Aim of the Work: To evaluate the effect of intravitreal injection of ranibizumab on diabetic macular edema (DME).
Patients and Methods
Type of the study: A longitudinal descriptive randomized study.
-Site of the study: The patients will be selected random from the outpatient clinic of National Eye Center of Ophthalmology in Rod El-Farag.
-Date and period of study: This study was conducted in March 2019.
-Size and type of sampling techniques to choose a representative sample: The study will include 20 eyes of 20 patients selected randomly with the following inclusion and exclusion criteria to receive a single intravitreal injection of ranibizumab.
-20 eyes with Type II diabetes mellitus with non-proliferative diabetic retinopathy (NPDR) and significant focal or diffuse DME with no foveal serous detachment confirmed by OCT.
Results: Twenty eyes attending the ophthalmic outpatient clinic between March 2019 and December 2019 were selected. They suffered focal or and diffuse DME, All eyes received primary dose of intravitreal injection of ranibizumab (0.5 mg).
Conclusion: The study showed that most patients did not show significant improvement in V/A rather than a significant decrease in central macular thickness after one injection and the improvement was considered less than those patients who had received multiple injections in other studies.
Keywords: ranibizumab, non-proliferative diabetic retinopathy,

INTRODUCTION
Macular edema occurs in a wide variety of ocular diseases, and an alteration in the blood–retinal barrier (BRB) leads to the accumulation of fluid in the extracellular space and the development of fluid-filled (cystoid) spaces in the outer plexiform layer and the inner nuclear layer of the retina are common findings in cystoid macular edema (CME). The term ‘cystoid’ rather than ‘cystic’ is used because the fluid-filled spaces do not possess the epithelial spaces that are present in a true cyst (I).
ME has been reported in 4.8% 6.8% of patients with diabetes (2).

Diabetic macular edema (DME) is the leading cause of vision loss in patients with diabetes in developed countries (3).

One of the pathological events that occur in diabetic retinopathy is the release of vascular endothelial growth factor (VEGF), which is induced mainly by hypoxia (4). It has been well established that VEGF plays a vital role in promoting neovascularization and increasing vascular permeability in diabetic eyes. The levels of ocular VEGF are correlated with both the growth rate and permeability of new vessels (5).

Previous studies have shown that vitreous samples from patients with DME have elevated VEGF levels. Furthermore, introduction of VEGF into normal primate eyes induces the same pathological processes as seen in diabetic retinopathy, namely, microaneurysm formation and increased vascular permeability (6).

It was also found that the growth of new vessels from the retina or optic nerve was thought to occur because of VEGF release into the vitreous cavity in response to ischemia (7).

AIM OF THE WORK

To evaluate the effect of intravitreal injection of ranibizumab on diabetic macular edema (DME).

PATIENTS AND METHODS

Date access:

Patients:

-Type of study: A longitudinal descriptive randomized study.

Study-site: Patients will be selected randomly from the outpatient clinic of the National Eye Center of Ophthalmology in Rod El-Frag.

-Date and period of study: This study was conducted in March 2019.

-Size and type of sampling techniques to choose a representative sample: The study will include 20 eyes of 20 patients selected randomly with the following inclusion and exclusion criteria to receive a single intravitreal injection of ranibizumab.

- Twenty eyes with type II diabetes mellitus with non-proliferative diabetic retinopathy (NPDR) and significant focal or diffuse DME with no foveal serous detachment confirmed by OCT.

Ethical considerations

- Explanation of the aim of the study to the patients in a simple way to be understood by the participants.

- Informed consent written in Arabic will be obtained from the participants with the approval of the ethical committee of the Faculty of Medicine.

- All data will be confidential and will not be used outside the study without patient approval.

- Participants had the right to withdraw from the study at any
time without giving any reason.

▪ All participants must be informed about possible side effects of injection, such as endophthalmitis, intraocular pressure elevation, retinal detachment, and ocular hemorrhage.

▪ No harmful manoeuvres were per ocular hemorrhage formed or used.

▪ Before injection complete ophthalmological examination was done for every patient.

**Eligibility for the study**

▪ Age eligible for Study: above 40 Years.

▪ Gender eligible for Study: Both genders were included.

**Inclusion Criteria**

▪ Patients with type II diabetes mellitus with non-proliferative diabetic retinopathy (NPDR) and focal or diffuse DME were confirmed using OCT.

▪ Glucose levels must be controlled and evaluated using glycosylated hemoglobin (HBA1c ≤ 7.5).

▪ Patients should have clear ocular media to allow for proper OCT scanning.

**Exclusion criteria:**

▪ Other retinal or macular pathology like ARMD or any occlusive disease affecting retina.

▪ Optic disc pathology due to chronic glaucoma.

▪ Patients previously treated with Argon laser or with intravitreal injection.

▪ Patients with proliferative diabetic retinopathy ± tractional retinal detachment and vitreoretinal traction.

▪ Patients with chronic renal failure or history of stroke were excluded from the study.

▪ Patients with media opacity affecting the cornea, lens, and vitreous that interfere with the evaluation of the macula by biomicroscopy, OCT.

▪ Patients with previous history of ocular surgeries.

**Follow up**

▪ Day 1, day 3, 1 week and 1 month.

▪ Each patient was followed up to detect changes in visual acuity, CFT and any complications.

**Follow up:**

▪ Best corrected visual acuity.
- Slit lamp examination and biomicroscopy.
- Applanation tonometry.
- Fundus examination.
- OCT macular thickness one month post-injection was performed in the same way, preoperatively, as data access documents.

**Results**

Twenty eyes attending the ophthalmic outpatient clinic between March 2019 and December 2019 were selected. They suffered focal or and diffuse DME. All eyes received primary dose of intravitreal injection of ranibizumab (0.5 mg).

8 males, 5 females, their ages ranges from 40-65 years with mean (49.3 ± 10.01). Log Mar visual acuity with mean (0.4 ± 0.26) before injection. CFT using OCT had a mean (323.90 ± 146.72 µm) before injection.

P-value >0.05: Non significant (NS);
P-value ≤0.05: Significant (S); P-value< 0.01: highly significant (HS)

*: Chi-square test; •: independent t-test

<table>
<thead>
<tr>
<th>Side</th>
<th>Count</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right</td>
<td>10</td>
<td>50.0%</td>
</tr>
<tr>
<td>Left</td>
<td>10</td>
<td>50.0%</td>
</tr>
</tbody>
</table>

Table (3) showing laterality

<table>
<thead>
<tr>
<th>Mean</th>
<th>Standard Deviation</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>49.30</td>
<td>10.01</td>
<td>52.50</td>
<td>33.00</td>
</tr>
</tbody>
</table>

Table showing age of patient’s data

<table>
<thead>
<tr>
<th>Mean</th>
<th>Std Dev</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>sphere before injection</td>
<td>81.25</td>
<td>26.00</td>
<td>87.50</td>
<td>20.00</td>
</tr>
<tr>
<td>cylinder before injection</td>
<td>-1.34</td>
<td>0.87</td>
<td>-1.00</td>
<td>-3.00</td>
</tr>
<tr>
<td>axis before injection</td>
<td>-0.41</td>
<td>3.48</td>
<td>0.50</td>
<td>-7.50</td>
</tr>
<tr>
<td>V/A before injection</td>
<td>0.40</td>
<td>0.26</td>
<td>0.40</td>
<td>0.05</td>
</tr>
<tr>
<td>macular thickness before injection</td>
<td>332.9</td>
<td>146.72</td>
<td>294.50</td>
<td>180.00</td>
</tr>
</tbody>
</table>

Table showing measures of patients, V/A, macular thickness before injection
Examples of cases:

Case 1

![Thickness Map Change Report, All Follow-Ups](image)

**Figure (39):** Pre intravitreal injection.

**Figure:** Post intravitreal injection.
DISCUSSION

An estimated 346 million people were affected by diabetes worldwide in 2011, and the number of people with diabetes is expected to double from 2005 to 2030 (9).

Diabetic retinopathy (DR) is the leading cause of vision loss in working-age adults, and diabetic macular edema (DME) is the most frequent cause of vision loss related to diabetes (10).

Many studies have evaluated intra-vitreal injection of ranibizumab in the treatment of DME using BCVA and CFT, and in our study, 20 eyes with focal/diffuse DME confirmed by OCT were injected by intra-vitreal injection of ranibizumab (0.5 mg).

Follow-up was performed at one day, three days, one week and one month after injection by ophthalmological examinations including BCVA, IOP assessment and OCT after one month.

In our study, patients of DME didn’t show statistically significant improvement in BCVA from (0.40 ± 0.26) to (0.46 ±0.30) and show statistically significant improvement in CFT as CFT decreased from (332.90 ± 146.7 μm) to (255.70 ± 133.11 μm).

Thus, both BCVA and CFT have significantly improved and many studies support these results, as in Patrao et al. (2016).

A study of 200 eyes of 164 consecutive patients with center-involving DME and VA ≤79 ETDRS letters (< 0.7 decimal), central subfield macular thickness (CST) ≥350 μm on Topcon 3D OCT 2000, initiated on a loading phase of three intravitreal ranibizumab injections and who had at least 6 months of follow-up were reviewed. The mean VA change at 12 months was +6.6 (± 13.35) letters (P =.0003). A total of 40.3% of patients (n = 77) gained ≥10 letters, 25.1% (n = 48) gained ≥15 letters, and 8.9% (n = 17) lost ≥10 letters and 6.3% (n = 12) lost ≥15 letters. At 12 months, the mean change in CFT were −133.9 (± 160.12) μm (P =.0001) (10).

Restore Extension Study In 2014, this study included 303 patients and found that ranibizumab was effective in improving and maintaining BCVA and CRST outcomes with a progressively declining number of injections over 3 years of individualized dosing (Schmidt-Erfurth et al., 2014).

Another study by Chun et al. A Pilot Study of Multiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema was made in 2006. Three intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) were administered on days 0, 1, and 2, and observation until month 24. The study revealed that ranibizumab therapy has the potential to maintain or improve BCVA and reduce retinal thickness in patients with center-involved clinically significant DME as at month 3, 4 of 10 patients gained ≥15 letters, 5 of 10 gained ≥10 letters, and 8 of 10 gained ≥1 letter. At month 3, the mean decrease in retinal thickness of the center point of the central subfield was 45.3±196.3 μm for the low-dose group and 197.8±85.9 μm for the high-dose group (11).

Shimura et al. (2013); Kim et al. (2011) have shown that intravitreal...
bevacizumab was more effective on the diffuse retinal thickening type than on the cystoid macular edema. In contrast, Koytak et al. (2013) showed that the SRD type was associated with a greater reduction in central foveal thickness than the diffuse retinal thickening type.

**CONCLUSION**

The study showed that most patients did not show significant improvement in V/A rather than a significant decrease in central macular thickness after one injection and the improvement was considered less than those patients who had received multiple injections in other studies.

**CONFLICT OF INTEREST:**

No potential competing interest was reported by the authors.

References


